AI assistant
ACHIEVE LIFE SCIENCES, INC. — Director's Dealing 2017
Jan 12, 2017
33882_dirs_2017-01-12_ca53d8e9-5b5e-4f3c-aff0-04f46df2c8a9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ONCOGENEX PHARMACEUTICALS, INC. (OGXI)
CIK: 0000949858
Period of Report: 2017-01-10
Reporting Person: Bencich John (CFO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-01-10 | Common Stock | M | 3125 | $0.00 | Acquired | 12609 | Direct |
| 2017-01-10 | Common Stock | F | 1021 | $0.63 | Disposed | 11588 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-01-10 | Restricted Stock Unit (RSU) | $ | M | 3125 | Disposed | 2019-06-18 | Common Stock (3125) | Direct |
Footnotes
F1: Represents shares of common stock acquired upon settlement of the restricted stock units ("RSUs") listed in Table II.
F2: Represents shares of common stock that have been withheld by the issuer to satisfy the tax liability in connection with the settlement of RSUs.
F3: Each restricted stock unit (RSU) represents a contingent right to receive one share of the issuer's common stock at settlement.
F4: Pursuant to the terms of the RSU, 25% of the total shares underlying the RSU vest annually on the later of: (i) each anniversary of January 1, 2015; and (ii) the first day thereafter during which the issuer's trading window is open.